1Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu, Korea.
2Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
3Department of Biomedical Science & BK21 plus KNU Biomedical Convergence Programs, Kyungpook National University, Daegu, Korea.
Copyright © 2018 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tissue | Target mechanism | PDC activity | Physiological condition | Reference |
---|---|---|---|---|
Heart | Increased PDK4 | (−) | Cardiac hypertrophy, diabetic cardiomyopathy | [ |
Lower PDC activity | (−) | Adaptation of a newborn heart | [ | |
Increased FOXO-PDK4 | (−) | Ang II induced cardiac hypertrophy | [ | |
Increased PDK4 | (−) | Insulin deficiency induced ketone body synthesis | [ | |
Ca2+ dependent PDP1 | (+) | Sympathetic stimulation | [ | |
Muscle | Increased PDK4 | (−) | Starvation | [ |
Post-exercise effect by higher gluconeogenesis | [ | |||
Obese and T2DM | [ | |||
Denervation in glycolytic muscle fibers | [ | |||
FOXO-PDK4 by decreased miR-182 | (−) | Obesity | [ | |
Phosphorylation of PDK | (−) | Insulin-resistant subject | [ | |
Phosphorylation of PDK | (−) | Ketone ester-based form of nutrition | [ | |
NAD+ precursor | (+) | Glucose oxidative phosphorylation | [ | |
Liver | Specific PDC knockdown | (−) | Liver-specific PDC deficiency resulting in hyperinsulinemia | [ |
Lipoamidase activity by SIRT4 | (−) | Decreased E2 component dihydrolipoyllysine acetyltransferase (DLAT) | [ | |
PDK4 deficiency | (+) | Improved glucose tolerance | [ | |
PDK2 deficiency | (+) | Improved insulin sensitivity & hepatic steatosis | [ | |
Brain | Increased PDK2/4 | (−) | Alzheimer's disease, stroke | [ |
PDC deficiency | (−) | Lactic acidosis and defected CNS | [ | |
Several identified mutants in human PDC | (−) | Peripheral neuropathy and in severe encephalopathy, myalgic encephalopathy/chronic fatigue syndrome | [ | |
Kidney | PDH E1α phosphorylation | (−) | T1DM | [ |
Increased PDK4 | (−) | Cisplatin induced nephrotoxicity | [ | |
Higher PDC activity | (+) | Hypertension | [ | |
Lower PDC activity | (−) | Diabetic nephropathy | [ |
PDC, pyruvate dehydrogenase complex; PDK, pyruvate dehydrogenase kinase; FOXO, Forkhead box O; PDP, pyruvate dehydrogenase phosphatase; T2DM, type 2 diabetes mellitus; NAD+, nicotinamide adenine dinucleotide; SIRT4, sirtuin 4; CNS, central nervous system; PDH, pyruvate dehydrogenase; T1DM, type 1 diabetes mellitus.